Wulf Otto BOECHER,Gerhard NEHMIZ,Wiebke SAUTER,Gerhard G. STEINMANN,Heike ZIMDAHL-GELLING
申请号：
US14540147
公开号：
US20150147295A1
申请日:
2014.11.13
申请国别(地区):
US
年份:
2015
代理人:
摘要：
The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) an interferon alfa and (c) ribavirin. Compound (1) is a selective and potent inhibitor of the HCV NS3 serine protease. The present invention also relates to methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in patients having genetic variations located near the IL28B gene, including SNP rs12979860 with a non-CC genotype and SNP rs8099917 with a non-TT genotype.
